Phase 1 Open-Label Dose-Escalation Study of Olaratumlab

Project: Research project

Project Details


A Phase 1, Open-Label, Dose-Escalation Study of Olaratumab as a Single Agent and in Combination with Doxorubicin, Vincristine/Irinotecan, or High-Dose Ifosfamide in Pediatric Patients with Relapsed or Refractory Solid Tumors (I5B-MC-JGDN)
Effective start/end date12/22/1512/22/20


  • Eli Lilly and Company

Fingerprint Explore the research topics touched on by this project. These labels are generated based on the underlying awards/grants. Together they form a unique fingerprint.